Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble

Grappling with the slow uptake of its constipation drug Trulance, Synergy Pharmaceuticals $SGYP has practically thrown in the towel saying that it does not anticipate receiving any takeover offers that sit well with its current market value and is thus hoping to renegotiate its hefty loan agreement.